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During the early phase of an inflammatory response, innate cells can use different strate-
gies to sense environmental danger.These include the direct interaction of specific activat-
ing receptors with pathogen-encoded/danger molecules or the engagement of cytokine
receptors by pro-inflammatory mediators produced by antigen presenting cells in the
course of the infection.These general recognition strategies, which have been extensively
described for innate myeloid cells, are shared by innate lymphoid cells (ILC), such as Natural
Killer (NK) cells.The family of ILC has recently expanded with the discovery of group 2 (ILC2)
and group 3 ILC (ILC3), which play an important role in the defense against extracellular
pathogens. Although ILC3 and NK cells share some phenotypic characteristics, the recogni-
tion strategies employed by the various ILC3 subsets have been only partially characterized.
In this review, we will describe and comparatively discuss how ILC3 sense environmental
cues and how the triggering of different receptors may regulate their functional behavior
during an immune response.
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INTRODUCTION
Innate lymphoid cells (ILC) represent a family of innate effec-
tors lacking recombination activating gene (RAG)-dependent
rearranged antigen receptors and myeloid and dendritic cell (DC)
markers. ILC are developmentally related as they all depend on
the common cytokine receptor γ-chain as well as on the tran-
scriptional repressor inhibitor of DNA binding 2 (ID2) for their
development. ILC comprise of different effector populations char-
acterized by distinct patterns of cytokine production and lineage-
specific master transcription factors, tailored to their exclusive role
in host defense. Thus, they closely resemble the heterogeneity of
CD4+ T helper (TH) cell subsets. ILC can be grouped into three
functionally distinct groups: group 1 ILC, among which Natural
Killer (NK) cells are the main population, group 2 ILC (ILC2),
and group 3 ILC (ILC3). ILC react promptly during infections
or inflammatory responses and play an important role in tissue
homeostasis, as well as in immune reactions against infectious
microorganisms and transformed cells (1). While the recognition
strategies employed by NK cells have been extensively investigated,
the analysis of the receptors mediating the activation of ILC3 and
ILC2 is still at the beginning. In this assay, we will review the
current understanding of the signals able to activate and induce
effector functions in ILC3 and discuss it in the context of NK cell
recognition strategies.
GROUP 3 ILC
Group 3 ILC or ILC3 are characterized by the expression of the
transcription factor RORγt, which is critical for their develop-
ment and function. A population of ILC3 emerges already dur-
ing embryogenesis and corresponds to the previously described
lymphoid-tissue inducer (LTi) cells, which are strictly required for
the prenatal development of lymph nodes (LN) and Peyer’s patches
(PP). In addition to RORγt, LTi cells express the IL-7 receptor (IL-
7R or CD127), the stem cell factor (SCF) receptor c-kit (or CD117),
IL-17, IL-22 and a number of tumor necrosis factor (TNF) family
members, such as lymphotoxin (LT) α1β2 (2–8). While LT is cru-
cial for the formation of secondary lymphoid structures, the role
of IL-17 and IL-22 during embryogenesis is not clear, as both IL-
22- and IL-17-deficient mice display normal lymphoid structures
(9). ILC3 expressing IL-17 and IL-22 have also been identified
after birth and are located mainly at mucosal surfaces (7, 10, 11).
Mouse ILC3 can be dissected according to CD4 and CCR6 (11, 12).
CCR6+ ILC3 share several features with LTi cells, being enriched
in IL-17 and CD4 expression. Conversely, CCR6− ILC3 do not
express IL-17 or CD4 but produce IL-22. Among CCR6− ILC3, a
particular subset has been described, which is characterized by the
expression of the NK cell activating receptor (actR) NKp46 and
partial expression of NK1.1, producing not only IL-22, but also
some IFN-γ (12–18). While all subsets depend for their develop-
ment on RORγt, only CCR6− ILC3 require the transcription factor
T-bet, which is important for the differentiation toward NKp46+
ILC3 (12, 17, 18). Mouse ILC3 display a certain level of plastic-
ity in vitro and in vivo (1, 19, 20). IL-7 and microflora have been
reported to stabilize RORγt expression in small intestine (SI) lam-
ina propria (LP) NKp46+ and NKp46− ILC3, enabling them to
maintain their phenotype of IL-22 producers. However, NKp46+
ILC3 from spleen or colon tend to lose RORγt expression while
acquiring a full NK cell phenotype, which renders them almost
undistinguishable from conventional NK cells. However, by using
RORγt fate mapping (RORγtfm) to visualize NKp46+ cells derived
from RORγt+ progenitors, it could be shown that a large fraction
of colon LP and a minority of splenic NKp46+ cells actually repre-
sent ILC3, which have lost RORγt expression, as indicated by their
phenotype of RORγtfm+ RORγt− cells (20).
Similar to their mouse counterpart, human ILC3 are character-
ized by the expression of RORγt, IL-7R, c-kit, LTα1β2, and IL-22.
Human fetal LTi, displaying LTi-like in vitro activity, express IL-17
and IL-22 but not CD4. After birth, human ILC3 can be mainly
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found not only in the gut LP but also in tonsils, from where
they have been mostly isolated and characterized. Tonsil ILC3 are
homogenously CD127hi, c-kit+, and LTα1β2+ and can be fur-
ther dissected according to the expression of NKp44 and CD56
(7, 16, 21, 22). Although in one of the first reports, human IL-22-
producing RORγt+ ILC3 were identified as Lin− CD56+ NKp44+
cells and termed NK-22 (16), tonsil and gut LP CD56− NKp44+
and CD56+ NKp44− cells are also enriched in RORC transcripts.
They display a partially overlapping phenotype compared to their
CD56+ NKp44+ counterpart, thus suggesting that a large fraction
of tonsil lineage (Lin)− CD127hi c-kit+ cells, which do not express
the NK cell marker CD94 or the ILC2 marker CRTH2, might be
bona fide ILC3 (21–23). It has been proposed that CD56− ILC3
might represent the counterpart of CD4+mouse LTi-like cells (7).
However, some major differences between the mouse and human
counterparts should be mentioned. In humans, ILC3 homoge-
nously express CCR6, while lacking CD4 (7, 16). IL-17-producing
ILC3 can be found among CD56− NKp44− ILC3 especially in fetal
LN and gut LP of patients with Crohn’s disease, but not in ton-
sils (21, 24). Importantly, IL-22 expression is strictly confined to
human NKp44+ ILC3 subsets (especially CD56+), which largely
co-express NKp46 (16, 21, 22). Conversely, mouse IL-22 is prefer-
entially expressed by NKp46− ILC3 (25). Moreover, in contrast to
the NKp46+ T-bet+ RORγt+mouse ILC3 subset, T-bet and IFN-γ
proteins are not produced ex vivo by tonsil-derived ILC3, although
expression can be induced after in vitro culture (7, 16, 19, 22). In
addition to the cytokines mentioned, human tonsil ILC3 have also
been shown to express IL-26, GM-CSF, TNF, CCL20, LIF, IL-5, and
IL-13. Intriguingly, human ILC3 produce consistent amounts of
IL-2, whose in vivo function remains to be elucidated (7, 16, 19, 22,
26). Similarities and differences among human and mouse ILC3
subsets in comparison with splenic or blood NK cells are depicted
in Table 1.
ILC3 FUNCTIONS
ROLE OF ILC3 FOR THE FORMATION OF SECONDARY LYMPHOID
ORGANS AND POST-NATAL INTESTINAL LYMPHOID CLUSTERS
LTi cells play a pivotal role during prenatal organogenesis of LN
and PP. The most important effector molecules for lymphoid
organogenesis are the TNF superfamily members, in particular
LTα1β2 which, by triggering the LTβ-receptor (LTβR) on mes-
enchymal stem cells, induces the expression of adhesion molecules
and chemokines, such as VCAM-1 and CXCL13. As a consequence,
B cells, T cells, and DC can be recruited to form the LN (36). In
addition, ILC3 are also required for post-natally developing intesti-
nal lymphoid organs such as cryptopatches (CP) and isolated
lymphoid follicles (ILF) (37). CP are lymphoid clusters located
in the LP in between the gut crypts and comprise mainly of ILC3
surrounded by a wall of DC. When B cells are recruited to CP, ILF
are formed, which represent important sites of T cell-independent
IgA production. While the formation of CP is independent of
the intestinal microbiota, formation of ILF requires signals from
intestinal bacteria (27, 38–42).
MAINTENANCE OF EPITHELIAL BARRIER FUNCTION
ILC3 are critically involved in the maintenance of the barrier func-
tion, due to the production of cytokines instructing epithelial
cell functions. Their ILC3 signature cytokine IL-22 is certainly
a main mediator of the cross talk between epithelial cells, immune
cells, and the commensal microflora. IL-22 belongs to the IL-10
family and binds the IL-22 receptor, a heterodimer compris-
ing of IL-10R2 and IL-22R1, which is exclusively expressed on
epithelial cells and signals mainly via STAT3. IL-22 induces the
production of antimicrobial peptides and proteins, such as β-
defensins, RegIIIβ and RegIIIγ, calgranulins S100A8, S100A9, and
lipocalin-2 by epithelial cells (43–46). Furthermore, IL-22 induces
epithelial cells to secrete elevated levels of mucus-associated mol-
ecules like Muc1, Muc3, Muc10, and Muc13, thus increasing the
mucus production, whereby the translocation of commensal bac-
teria across the epithelial barrier during inflammation is reduced.
In vivo, IL-22 induces the migration of epithelial cells and pro-
motes wound healing during inflammation (47–50). Similar to
its role in the intestine, IL-22 exerts tissue repairing functions
also during liver inflammation (51–53). The ILC-mediated reg-
ulation of epithelial cell functions is strictly linked to their role
in the containment of commensal and pathogenic microbes.
Indeed, an intact ILC compartment is important for preventing
peripheral dissemination and systemic inflammation of commen-
sal bacteria such as Alcaligenes species, residing within PP and
mesenteric LN of healthy humans and mice (54). Moreover, it
was shown that IL-22 from ILC3 is important to contain the
expansion of commensal-segmented filamentous bacteria (SFB),
known to promote Th17 cells (55). On the other hand, micro-
biota can modulate production of IL-22 by ILC3 (25), although
ILC3 development seems to be independent of gut flora or
SFB (11, 56).
ILC3 also play an important role in the defense against pathogen
infections, such as Citrobacter rodentium, a murine pathogen
that models human enterohemorrhagic and enteropathogenic
Escherichia coli infections. Protection against C. rodentium is
mediated by IL-22, which is mainly produced by NKp46− ILC3 in
an IL-23-dependent manner (46, 57). Despite initial evidences for
a role of NKp46+ ILC3 in the defense against C. rodentium infec-
tion (14, 16), these cells appear to be dispensable (12). Although T
cells also importantly contribute to produce IL-22 after infection,
early production of IL-22 is crucial for C. rodentium resistance,
as Il22-/- mice rapidly succumb within the first 8–12 days after
infection (46, 58).
IFN-γ produced by T-bet-dependent CCR6− ILC3 has
been shown to contribute to the response against Salmonella
typhimurium infection in mouse (12). Other reports have also
recently outlined the importance of IL-17A and IL-17F pro-
duction by ILC3 for the protection against mucosal Candida
infections (59).
Due to their ability to modulate epithelial cell functions as
well as to respond against commensal bacteria and pathogens,
ILC3 also participate in the complex regulation of inflamma-
tory bowel disease (IBD), displaying rather a dual role. Indeed,
several investigators have suggested a protective role for IL-22,
likely produced by ILC3, in innate and adaptive IBD models
(47, 60). On the other hand, expression of IL-17 and IFN-γ
from ILC3 has been implied to drive inflammation in innate
IBD models, such as anti-CD40 or Helicobacter hepaticus-induced
colitis (20, 61).
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Table 1 | Phenotype of LTi, ILC3 subsets, and NK cells in human and mouse.
Mouse Human
Fetal LTi NCR− ILC3 NCR+ ILC3 Spleen NK cells Fetal LTi NCR− ILC3 NCR+ ILC3 Blood NK cells
SURFACE MARKERS
CD127 (IL-7Rα) + + + − + + + lo/−
CD117 (c-Kit) + + + lo/− + + + lo/−
CD122 (IL-2Rβ) ND lo lo + ND lo lo +
NK1.1/CD161 − − lo/− + ± + + +/lo
CCR6 + ± − − + + + −
NKG2D − − + + − lo/− lo/− +
NKp30 NA NA NA NA ± ± + +
NKp44 NA NA NA NA lo/− − + +a
NKp46 − − + + − ± + +
CD56 NA NA NA NA lo/− ± ± +
Perforin − − − +/lo − − − +/lo
CD16 ND − − ± − − − ±
Ly49/KIR − − − ± − − − ±
CD94 ND − ± ± − − − ±
CD4 + ± − − − − − −
RANKL + + + lo/− + + + −
CYTOKINES
TNF + + + + + + + +
IFN-γ − lo/− lo/− + − lo/− lo/− +
IL-17 + ± − − + lo/− lo/− −
IL-22 + + + − + − + −
GM-CSF ND ND ND ND ND + + +
IL-2 ND ND ND ND ND + + −
LTA/LTB + + + lo + + + lo
TRANSCRIPTION FACTORS
T-bet − ± + + − − − +
Eomes − − − + − − − +
RORγt + + + − + + + −
Gata-3 − lo lo lo/− lo/− lo/− lo/− lo/−
AhR + + + − + + + −
NCR+ refers to NKp46+ ILC3 in mouse and NKp44+ ILC3 in humans. + Indicates high level expression, − indicates no expression, ± indicates bimodal expression,
and lo indicates low expression of the molecules according to published reports (1, 4, 6, 7, 11, 13, 14, 16–18, 21–23, 25, 27–35).
NA, not applicable as gene is not conserved in the respective species. ND, not described.
aExpressed only on activated-NK cells.
AhR, aryl hydrocarbon receptor; CCR6, C–C chemokine receptor type 6; GM-CSF, granulocyte-macrophage-colony stimulating factor; IFN-γ, interferon-γ; IL, interleukin;
KIR, killer-cell immunoglobulin-like receptor; LT, lymphotoxin; LTi cell, lymphoid-tissue inducer cell; NK cell, natural killer cell; RANKL, receptor activator of NF-κB ligand;
RORγt, retinoic acid receptor-related orphan receptor-γt.
REQUIREMENTS FOR ILC3 ACTIVATION
Although many reports have clarified the functions of ILC3 and
their role in the defense against pathogens, their receptor repertoire
and the main signaling pathways able to trigger effector functions
in ILC3 have not been extensively investigated. It was shown that,
similar to NK cells, ILC3 can be mainly activated by cytokines
released by the epithelium or antigen presenting cells (APC). More
recently, receptors mediating a direct sensing of the environment
by ILC3 have been also described. Here, we will revise the main
findings concerning the recognition strategies that enable ILC3 to
mediate their effector functions in response to perturbation of the
epithelial barrier.
CYTOKINE RECEPTORS
Both human and mouse ILC3 constitutively express the receptors
for IL-7 and TSLP (IL-7R or CD127), IL-15/IL-2 (IL-2Rβγ), IL-23
(IL-23R), IL-1 (IL-1R), and SCF (c-kit). Among these cytokines,
IL-7, TSLP, and SCF are required for ILC3 development and
induce, together with IL-2/IL-15 and IL-1, proliferation of ILC3.
Conversely, IL-23 and IL-1 play an important role in inducing
ILC3 effector functions in vitro and in vivo (7, 8, 13, 16, 19, 62,
63). IL-23 is a heterodimer composed of subunits p19 and p40.
The cellular sources are predominantly activated macrophages and
DC (64). IL-23 was initially described as the main stimulus for
induction of IL-22 expression in ILC3 (13, 16). Nevertheless, in
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IL-23p19-deficient mice or in wild-type mice treated with neu-
tralizing anti-IL-23R antibody, the production of IL-22 by ILC3
is unaffected at steady state, suggesting that constitutive produc-
tion of IL-22 by ILC3 is IL-23-independent (25). However, IL-23
becomes an important stimulus for innate production of IL-22 and
IL-17 during C. rodentium and H. hepaticus infection (46, 61). In
humans, IL-23 promotes IL-22 expression in vitro, together with
IL-1 (65). Moreover, it induces IL-17 production in CD56− ILC3
isolated from the gut LP of patients affected by Crohn’s disease
(24). Altogether, these data imply the IL-23 axis as an important
pathway of ILC3 activation during inflammation.
IL-1β is a key pro-inflammatory cytokine, which can be pro-
duced by different cell types (66). IL-1β does not only induce
ILC3 proliferation, especially in combination with IL-7 and IL-
2/IL-15 (19), but also induces the accumulation and activation
of ILC3 during the course of H. hepaticus infection (67). IL-1β
synergizes with IL-23 or IL-7 in stimulating ILC3 to produce IL-
22 (22, 23). The importance of IL-1β for cytokine expression by
ILC3 was also demonstrated by the decrease in basal as well as
in IL-23-induced production of IL-22 observed in the presence
of anti-IL-1R1-blocking antibodies or in mice deficient for IL-1R
adaptor molecule, MyD88 (56).
In addition to their role in development of ILC3, IL-7, TSLP,
and SCF also likely contribute to ILC3 maintenance post-natally
(68). IL-7 enhances LTα1β2 expression (69, 70) and stabilizes
in vivo the expression of RORγt on ILC3, thus preventing their
conversion into IFN-γ-producing ILC3 (20). The main source of
these cytokines is mainly non-hematopoietic cells such as fibrob-
lasts, epithelial cells, and different types of stromal cells. Thus,
it would be interesting to understand whether these cells get
directly or indirectly instructed from ILC3 to produce IL-7, TSLP,
and SCF.
ENVIRONMENTAL SENSORS
Apart from cytokine receptors, ILC3 are capable of directly rec-
ognizing environmental cues. Here, we will describe the main
receptors that have been reported to enable ILC3 accomplishing
this task.
Aryl hydrocarbon receptor
Both mouse and human ILC3 express the transcription factor
aryl hydrocarbon receptor (AhR), belonging to the basic helix–
loop–helix/Per–Arnt–Sim (bHLH/PAS) family of proteins. After
engaging its ligand, AhR translocates from the cytoplasm to the
nucleus where it pairs with AhR nuclear translocator (ARNT or
HIF-1β) and then binds to xenobiotic response elements (XRE)
present in the regulatory regions of AhR target genes (71, 72).
Relevant target genes encode xenobiotic-metabolizing enzymes,
including the cytochrome p450 superfamily members CYP1A1,
CYP1A2, and CYP1B1. Several endogenous molecules, includ-
ing metabolites of tryptophan and arachidonic acid have been
shown to activate AhR. Among exogenous molecules function-
ing as AhR agonists, plant phytochemicals, such as polyphenols
and glucosinolates as well as environmental toxins (dioxin) have
been described. Moreover, bacterial metabolites have also been
reported to display AhR agonist functions. Thus, AhR mainly acts
as an environmental sensor (71, 73).
The number of post-natal ILC3 as well as the development
of CP and ILF is drastically reduced in Ahr-deficient mice. Con-
versely, the number of fetal LTi and secondary organ development
is not perturbed. The decrease in ILC3 observed in Ahr-deficient
mice is not evident until the third week, suggesting that environ-
mental stimuli may contribute to the differentiation, survival, and
post-natal expansion of ILC3. Indeed, ILC3 from Ahr-deficient
mice displayed lower expression of c-kit and IL-7R, as well as
of the anti-apoptotic genes Bcl2 and Bcl2l1. Moreover, IL-22 but
not IL-17 expression by ILC3 in SI and colon was consistently
reduced in Ahr-deficient mice (28–30). Despite the evidence of
a central role of AhR in the maintenance and functions of ILC3,
the endogenous and exogenous ligands driving this process still
remain unclear. Kiss et al. have proposed a major role for AhR lig-
ands derived from food components. Indeed, they could show
that mice fed with phytochemical-free diets had a phenotype
similar to Ahr-deficient mice (28). However, by using a differ-
ent diet to feed mice, these data could not be confirmed by Lee
et al. (29). Can ILC3 sense commensal bacteria via AhR? AhR lig-
ands from bacterial metabolites can modulate ILC3 functions. It
was recently shown that under conditions of unrestricted trypto-
phan availability, Lactobacilli species can produce an AhR ligand
(indole-3-aldehyde) enhancing IL-22 expression in ILC3, which
allows the survival of mixed microbial communities and provides
colonization resistance to Candida albicans (74). In the future, it
would be of great interest to understand whether ILC3 can employ
AhR-dependent strategies to directly sense pathogens and produce
effector cytokines.
Toll-like and other pattern recognition receptors
Pattern recognition receptors (PRR), such as Toll-like receptors
(TLR), are mainly expressed on APC, such as macrophages or DC.
Engagement of PRR by pathogen-derived ligands induces APC
activation and production of pro-inflammatory cytokines (75).
TLR2 and the C-type lectin receptor dectin-1 (or CLEC7A) bind
β-glucans, i.e. structural cell wall polymers of fungi, and are impli-
cated in the immune response to Candida albicans (76). Since both,
the IL-17/IL-22 axis and ILC3 play a role in the defense against
Candida albicans infection (59, 77), the role of PRR recognizing
fungal components has been investigated. Injection of TLR2 and
dectin-1 ligands can boost IL-17 and IL-22 production by mouse
ILC3 as well as by γδ T cells (10, 78). However, while mouse IL-17-
producing γδ T cells express both receptors, and directly respond
to TLR2 stimulation, mouse ILC3 apparently lack TLR2 and are
not directly activated by TLR2 ligands (26). By using quantitative
RT-PCR, Crellin et al. observed broad expression of many TLR
transcripts, including TLR1, 2, 5, 6, 7, and 9 by ex vivo isolated
human ILC3 as well as by cloned ILC3 lines, although the degree
of expression was still lower than on monocytes. Interestingly, only
TLR2 agonists were able to induce cytokine production by human
ILC3 in the presence of cytokines like IL-2, IL-15, and IL-23 (26).
Thus, TLR2 engagement in ILC3 seems to act as a costimulus,
rather than as a trigger on its own, as is the case when TLR ago-
nists stimulate myeloid cells. This finding is in line with previous
observations on other lymphocyte subsets, such as T cells and NK
cells (79, 80). TLR2 triggering induces different responses depend-
ing on the cytokine employed as costimulation. TLR2 engagement
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induces IL-5 and IL-13 in the presence of exogenous IL-2 or IL-15,
but not of IL-23. In contrast, IL-22 can be induced by either com-
bination of signaling pathways (26). In light of its role in fungi
recognition, TLR2 engagement might contribute to human ILC3
activation during Candida infection. Moreover, polymorphisms
of TLR2 are linked with the disease phenotype in IBD. However, it
remains to be established whether TLR2 activation of ILC3 plays
a role in vivo (81).
NK cell activating receptors
Both human and mouse ILC3 subsets express NK cell actR, which
have been described to mediate NK cell cytotoxicity and produc-
tion of cytokines, such as IFN-γ and TNF, upon recognition of
cognate cellular and viral ligands. NK cell actR include NK group
2, member D (NKG2D), DNAX accessory molecule (DNAM)-1,
2B4, CD94/NKG2C, and the natural cytotoxicity receptors (NCR),
namely NKp46 (also known as NCR1 or CD335), NKp44 (also
known as NCR2 or CD336), and NKp30 (also known as NCR3
or CD337). Human activating killer Ig-like receptors (KIR) and
NKp80 or mouse Ly49 and NK1.1 also function as actR in NK
cells (82, 83).
As previously mentioned, a subset of T-bet-dependent mouse
ILC3 expresses NKp46 and has also been named NCR+ ILC3.
NKp46+ ILC3 isolated from the SI LP of B6 mice largely co-
express NKG2D and 2B4, while only a part of these cells co-express
NK1.1 (15, 16). As engagement of actR induces effector functions
in NK cells, actR triggering was also explored as a potential acti-
vating stimulus in ILC3. Engagement of NKp46, NK1.1, or 2B4
did not succeed in inducing IFN-γ or IL-22 expression in SI LP
NKp46+ ILC3 (63). Conversely, NK1.1 but not NKp46 triggering
was sufficient to drive IFN-γ and TNF, but not IL-22, expression
in splenic NKp46+ RORγtfm+ RORγt− ILC3 (22). A consistent
fraction of human ILC3 derived from tonsils and gut LP expresses
NKp44, NKp46, and NKp30, although to lower levels compared
to NK cells. NKG2D or CD94/NKG2C is conversely not expressed
by human ILC3. Thus, among NK cell actR, human ILC3 prefer-
entially express NCR (7, 16, 21, 22, 65). In a recent study, we could
show that among the different NK cell actR expressed by ILC3,
namely NKp46, NKp30, and CD2, only engagement of NKp44
results in a strong cytokine response by ILC3 (22). Thus, the basic
biology of NKp44 and its role on human ILC3 will be further
discussed.
NKp44
NKp44 belongs to the NCR family, which represents type I mem-
brane proteins of the immunoglobulin superfamily. NKp44 is not
conserved between humans and mouse. In contrast to the other
NCR, NKp44 is not expressed on resting human NK cells but it
is up-regulated on their surface after IL-2 stimulation and upon
engagement mediates the killing of susceptible tumor cell lines
(84, 85). Conversely, NKp44 is detectable ex vivo on ILC3 and
selectively marks the IL-22-producing subset in human tonsil and
gut LP (16, 21, 22). NKp44 as well as NKp30 and NKp46 com-
prises of three domains: the extracellular ligand-binding domain,
the transmembrane one, and a short cytosolic tail lacking intra-
cellular signaling activity and therefore associating with ITAM-
containing adaptor proteins (82, 83). Engagement of NCR results
in recruitment and activation of zeta chain-associated protein
kinase 70 (ZAP-70) and spleen tyrosine kinase (SYK), leading to
the activation of several downstream signaling molecules, includ-
ing phosphatidylinositol 3-kinase (PI3K) and phospholipase C
(PLC)-γ1 or PLCγ2 (86). Unique among the NCR, NKp44 is cou-
pled to a dimer of the ITAM-containing adaptor DNAX-activation
protein (DAP)12 for downstream signal transduction and trigger-
ing of NKp44 in IL-2-activated NK cells leads to cytotoxicity of
tumor target cells (84). Engagement of NKp44 in ex vivo isolated
ILC3 is sufficient to induce cytokine production, demonstrating
that ILC3 can directly sense the environment and be activated in
the absence of pro-inflammatory cytokines (22). NKp44 trigger-
ing in ex vivo isolated ILC3 selectively induces the expression of
TNF and IL-2 as well as a coordinated pro-inflammatory program,
while cytokine stimulation (IL-23, IL-1, and IL-7) preferentially
induces IL-22 and GM-CSF expression. Thus, ILC3 are able to
switch between IL-22 or TNF production, depending on the trig-
gering stimulus. However, combined engagement of NKp44 and
cytokine receptors results in a strong synergistic effect both at
transcriptome and protein level (22).
Which ligand is recognized by NKp44 expressed by NK cells
or ILC3? Although several tumor cells and bacteria can bind
NKp44–Ig fusion protein (87, 88), and NKp44 blocking via specific
antibodies can decrease activated-NK cell-mediated cytolysis (84),
as well as ILC3 cytokine production (22), the identity of NKp44
ligands triggering NK cells and ILC3 remains elusive. Discover-
ing cellular ligands of the NCR still represents a great challenge,
and only few cellular and viral ligands have been identified (89),
such as the NKp30 ligands BAT3 (or BAG6) and B7-H6, which
are expressed or released by tumor cells (90, 91). NKp44 has been
described to bind to sialylated and sulfated cellular proteoglycans,
hemagglutinin (HA) from influenza virus, and other viral HA-
neuraminidase proteins, and HA engagement of NKp44 results in
NK cell activation (92, 93). Surprisingly, influenza virus HA does
not trigger NKp44-mediated cytokine expression in ILC3 (22).
However, as sialic acid moieties attached to the stalk domain of
NKp44 contribute directly to HA binding (93), glycosylation pat-
tern of NKp44 expressed by NK cells or ILC3 should be analyzed.
In addition, an inhibitory ligand of NKp44, namely proliferat-
ing cell nuclear antigen (PCNA), has also been reported (94).
Very recently, a truncated form of the mixed lineage leukemia-
5 (MLL5) protein has been described being an activating ligand of
NKp44 and named NKp44L (95). Unlike MLL5, which is present
in the nucleus and cytosol, NKp44L displays a unique C-terminal
sequence that is required for its localization at the cell surface
and its interaction with NKp44. NKp44L expression is present
on the surface of several tumor cell lines, which are susceptible
to NK cell-mediated lysis and their killing can be reduced using
an anti-NKp44L antibody (95). As the nature of the NKp44 lig-
ands eliciting inflammatory signatures in ILC3 remains elusive, it
would be of great interest to test whether NKp44L could also trig-
ger ILC3 cytokine production. In particular, it would be important
to investigate whether, in addition to tumor cell lines, NKp44L
would be also up-regulated on damaged or infected epithelial
cells. NKp44 recognition of ligands expressed by microorganisms
or intestinal epithelial cells could participate in fighting selected
pathogens, restraining gut microflora, or even regulating epithelial
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FIGURE 1 | Strategies of ILC3 to sense the environment. LP-resident
ILC3 can sense the environment via their receptors for cytokines, actR,
AhR, and PRR. Depending on the triggering stimulus production of pro- and
anti-inflammatory cytokines can be induced, which mediate the response
to pathogens and promote tissue homeostasis/repair.
cell homeostasis at steady state or during inflammation. In this
context, it was recently reported that NKp44L is present on the
surface of normal human articular chondrocytes (96). As ILC3
accumulate in the synovial fluid of patients affected by rheumatoid
arthritis and can mediate proliferation of fibroblast-like synovio-
cytes in a TNF- and IL-22-dependent manner (97), the role of
NKp44–NKp44L interactions in mediating this process should
be investigated. Revealing the nature of NKp44 ligands relevant
for ILC3 activation would enable us to better understand ILC3
functions in steady state and during inflammatory conditions.
CONCLUSION
In conclusion, ILC3 are important innate effectors involved in the
defense against extracellular pathogens as well as in the main-
tenance of the epithelial barrier. ILC3 can be activated directly
after engagement of environmental sensors and/or in response to
epithelial and APC-derived cytokines. Subsequently, they produce
their signature cytokine IL-22 as well as other mediators, thus
being able to modulate both, immune- as well as epithelial cell
functions at mucosal interfaces (Figure 1).
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